Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.34 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | ILK | Q13418 | 1/20 | 0.32 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29654423 | 1.00 | CFTR (0.46) | CFTRMAPTSOS1CISD2MBOAT4 | |
| SCHEMBL24525175 | 0.89 | CFTR (0.40) | CFTRMAPTCISD2MBOAT4NR1H2 | |
| SCHEMBL29654494 | 0.88 | ASPH (0.36) | CFTR | |
| SCHEMBL24525401 | 0.88 | ASPH (0.36) | CFTR | |
| SCHEMBL25486986 | 0.88 | CFTR (0.37) | CFTRSOS1ILKCGAS | |
| SCHEMBL29654642 | 0.85 | CFTR (0.48) | CFTRMAPTSOS1ABL1SRC | |
| SCHEMBL24525284 | 0.85 | CFTR (0.48) | CFTRMAPTSOS1ABL1SRC | |
| SCHEMBL29654600 | 0.83 | CFTR (0.48) | CFTRMAPTSOS1CISD2MBOAT4 | |
| SCHEMBL24525183 | 0.83 | CFTR (0.48) | CFTRMAPTSOS1CISD2MBOAT4 | |
| SCHEMBL24525066 | 0.79 | CFTR (0.51) | CFTRMAPTMBOAT4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845761-B2 | Tricyclic pyridones and pyrimidones | ERASCA, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230107642-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2022133345-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022133345-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107642-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | KRAS, NRAS, HRAS | CFTR 1205/4885MAPT 4642/4885SOS1 279/4885 |
| US-11845761-B2 | Tricyclic pyridones and pyrimidones | KRAS, NRAS, HRAS | CFTR 1205/4885MAPT 4642/4885SOS1 279/4885 |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | KRAS, NRAS, HRAS | CFTR 1205/4885MAPT 4642/4885SOS1 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.